The Program — What Happens Next — The Evidence — About Dr. Hare — Why Physician-Led The Limitless Protocol Why Limitless Services — Hormone Therapy — Low Testosterone — Testosterone Pellets — Women's Hormone Therapy — Medical Weight Loss — Tirzepatide — Semaglutide — Moving Your GLP-1 Care — Peptide Therapy — Peptide Menu — Cognitive Peptides — IV Therapy & NAD+ — NAD+ IV near Chattanooga — Cost & Payment Research — Retatrutide Update — Peptide Reclassification Update — The Case for Creatine Locations Assessment Request a consultation
Field Notes · Regulatory

Are peptides legal in 2026?
A physician's guide.

On April 23, 2026, twelve clinically meaningful peptides — spanning the tissue-repair and GH-axis categories — were removed from the FDA's Category 2 restricted compounding list. Note: this page was updated on May 14, 2026 to reflect verified guidance that certain GH-axis agents discussed in early press coverage remain not currently legal for human compounding and require full FDA rulemaking before that changes. See the GH-axis evidence brief.

Update, November 5, 2026: on October 30, HHS published an interim enforcement policy covering six peptides: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. DSIP, the seventh peptide FDA's advisory committee reviewed, is not covered. HHS says it does not intend to take enforcement action against compounding that meets the policy's conditions until a final rule addresses each peptide. The policy is not binding, the Federal Register notice calls it a draft and sets a two-week comment period, and none of the six has been added to the 503A bulks list.

If you've followed peptides at all over the last 18 months, you've watched the conversation get louder, weirder, and more confusing. Patients have asked me three questions repeatedly: Are these things legal? Are they safe? And how do I get them without ending up in the gray market? Here is the plain-English version of what changed on April 23 and what didn't.

What actually changed on April 23

For the past several years, the FDA had placed certain peptides on Category 2 — a status that, in practical terms, made compounding pharmacies unwilling to prepare them under either Section 503A (traditional patient-specific compounding) or 503B (registered outsourcing). Following a public review process and a February 27, 2026 announcement from HHS, twelve peptides came off Category 2 effective April 23.

That includes the workhorses of physician-led peptide medicine:

What didn't change

Reclassification is not the same as FDA approval. The peptides removed from Category 2 are still not FDA-approved drugs in the way that, say, semaglutide or tesamorelin are. They are prescription therapeutics: they need a valid prescription, an evaluation, an indication, and physician oversight. None of that infrastructure went away. None of it should.

"What changed is the lane. The standard for using these well — physician evaluation, documented sourcing, defined monitoring — is exactly what it was on April 22."

The other thing that didn't change: tesamorelin. Tesamorelin has long been FDA-approved for HIV-associated lipodystrophy and is dispensed under standard prescription. Its place in our visceral-fat protocol has been stable through this whole regulatory cycle.

What this means if you've been considering peptide therapy

For most patients I see, three things matter most:

The Limitless position, in one paragraph

Compounded peptides are real medicine when used correctly: a documented indication, a licensed pharmacy of origin, a written prescription, an informed-consent document, a defined monitoring plan, and a stop point. We do not stock retail peptides, sell at the front desk, or refer to online vendors. Every peptide a Limitless patient receives originates from a state-licensed 503A or FDA-registered 503B pharmacy under prescription written by me. That standard didn't change on April 23. The lane it operates in did.

What's next: the July PCAC review

Update, October 6, 2026: the July meeting has taken place, and the committee recommended six of the seven peptides it reviewed. The recommendation is advisory; our post-vote analysis covers what it changes. The two paragraphs below are kept as they were published in May.

The April 23 reclassification was the procedural step. The substantive review is scheduled for the July 23–24, 2026 PCAC meeting, where the committee will weigh formal status for these peptides under 503A and 503B compounding rules. The most likely outcome — though no committee outcome is guaranteed — is continued legal access through licensed compounding with structured monitoring expectations. We'll publish a follow-up note once the meeting concludes.

If you've been waiting for the regulatory picture to settle before considering peptide therapy, the current environment is the most stable it's been in three years. If you've been doing it without a physician — through a vendor, a clinic-in-a-box, or a friend — this is a good moment to bring it back into the medical lane.

"These are useful tools. They are not toys. Respect what they can do, build a protocol around evidence and monitoring, and they earn their place in performance medicine. That is the way we do it at Limitless." — Joshua Hare, DO · Medical Director

Ready to do this the right way?

A 30-minute consultation with Dr. Hare, a full lab panel, and a physician-built protocol — sourced, prescribed, and monitored to a documented standard.

Request a consultation

Take the Assessment · 90 sec

This article is for educational purposes and does not constitute medical advice. Compounded peptides described are not FDA-approved drugs. Treatment decisions are made on an individual basis after evaluation by Joshua Hare, DO. Last reviewed May 3, 2026.